Les otorhinolaryngologistes français, acteurs du développement durable
Nicolas Leboulanger(Hôpital Necker-Enfants Malades), B. Gardini(Clinique Pasteur), O. Mazzaschi(Inserm), M. Veyrat(Fondation Ophtalmologique Adolphe de Rothschild), Y. Camhi(Fondation Ophtalmologique Adolphe de Rothschild), N. Clerc(Centre National de la Recherche Scientifique), Philippe Lesnik(Inserm)
Annales françaises d Oto-rhino-laryngologie et de Pathologie Cervico-faciale
October 1, 2023
Cited by 0
Related Papers
Lipoprotein(a) as a cardiovascular risk factor: current status
|European Heart Journal|2010|1.8k
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
|European Heart Journal|2011|1.2k
The eROSITA X-ray telescope on SRG
|Springer Link (Chiba Institute of Technology)|2021|666
Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma
|International Journal of Pediatric Otorhinolaryngology|2009|235
Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30‐year nationwide cohort of 1478 patients under 18 years of age
|British Journal of Haematology|2016|130